Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS)

BMC Endocrine Disorders

Martin M Miner¹  Dat Nguyen²  Harvey Kushner²  Gary Blick⁵  Mohit Khera⁴  Rajib K Bhattacharya³ 

[1] Miriam Hospital Men's Health Center, 164 Summit Avenue, Providence, RI 02906, USA;Auxilium Pharmaceuticals, 40 Valley Stream Parkway, Malvern, PA 19355, USA;University of Kansas Medical Center, 3901 Rainbow Blvd, MS2024, Kansas City, KS 66160, USA;Scott Department of Urology, Baylor College of Medicine, 6620 Main Street, Suite 1325, Houston, TX 77030, USA;Circle Medical LLC, 153 East Avenue, Suite 32, Norwalk, CT 06851, USA

关键词: fasting glucose;    testosterone deficiency;    hypogonadism;    Testim;    TRiUS registry;    testosterone replacement;    testosterone gel;    obesity;    metabolic syndrome;    Testosterone;   

Others  :  1086484
DOI  :  10.1186/1472-6823-11-18

 received in 2011-07-22, accepted in 2011-11-01,  发布年份 2011

【 摘 要 】

Background

Recent evidence suggests that there may be a bidirectional, physiological link between hypogonadism and metabolic syndrome (MetS), and testosterone replacement therapy (TRT) has been shown to improve some symptoms of MetS in small patient populations. We examined the effect of 12 months of TRT on MetS components in a large cohort of hypogonadal men.

Methods

Data were obtained from TRiUS (Testim^® Registry in the United States), a 12-month, multicenter, prospective observational registry (N = 849) of hypogonadal men prescribed Testim 1% testosterone gel (5-10 g/day). Data analyzed included age, total testosterone (TT), free testosterone (FT), sex hormone-binding globulin (SHBG), and MetS components: waist circumference, blood pressure, fasting blood glucose, plasma triglycerides, and HDL cholesterol.

Results

Of evaluable patients (581/849) at baseline, 37% were MetS+ (n = 213) and 63% were MetS- (n = 368). MetS+ patients had significantly lower TT (p < 0.0001) and SHBG (p = 0.01) levels. Patients with the lowest quartile TT levels (<206 ng/dL [<7.1 nmol/L]) had a significantly increased risk of MetS+ classification vs those with highest quartile TT levels (≥331 ng/dL [≥11.5 nmol/L]) (odds ratio 2.66; 95% CI, 1.60 to 4.43). After 12 months of TRT, TT levels significantly increased in all patients (p < 0.005). Despite having similar TT levels after TRT, only MetS+ patients demonstrated significant decreases in waist circumference, fasting blood glucose levels, and blood pressure; lowest TT quartile patients demonstrated significant decreases in waist circumference and fasting blood glucose. Neither HDL cholesterol nor triglyceride levels changed significantly in either patient population.

Conclusion

Hypogonadal MetS+ patients were more likely than their MetS- counterparts to have lower baseline TT levels and present with more comorbid conditions. MetS+ patients and those in the lowest TT quartile showed improvement in some metabolic syndrome components after 12 months of TRT. While it is currently unclear if further cardiometabolic benefit can be seen with longer TRT use in this population, testing for low testosterone may be warranted in MetS+ men with hypogonadal symptoms.

【 授权许可】

   
2011 Bhattacharya et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C: Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006, 60(7):762-769.
• [2]Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM: Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010, 95(6):2536-2559.
• [3]Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001, 86(2):724-731.
• [4]Guay AT: The emerging link between hypogonadism and metabolic syndrome. J Andol 2009, 30(4):370-376.
• [5]National Cholesterol Education Program, National Institutes of Health: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106(25):3143-3421.
• [6]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
• [7]Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA: Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109(4):551-556.
• [8]Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT: Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004, 27(5):1036-1041.
• [9]Ding EL, Song Y, Malik VS, Liu S: Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2006, 295(11):1288-1299.
• [10]Zitzmann M: Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol 2009, 5(12):673-681.
• [11]Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000, 85(8):2839-2853.
• [12]Kapoor D, Goodwin E, Channer KS, Jones TH: Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006, 154(6):899-906.
• [13]Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH: The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007, 156(5):595-602.
• [14]Heufelder AE, Saad F, Bunck MC, Gooren L: Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Andol 2009, 30(6):726-733.
• [15]Aversa A, Bruzziches R, Francomano D, Spera G: Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome. J Endocrinol Invest 2010, 33(11):776-783.
• [16]Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G: Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010, 7(10):3495-3503.
• [17]Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS: Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011, 34:828-837.
• [18]Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F: Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blind placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010, 73(5):602-612.
• [19]Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, Forti G, Mannucci E, Maggi M: Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011, 8(1):272-283.
• [20]Miner MM, Khera M, Bhattacharya R, Blick G, Kushner H: Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med 2011, 123(3):17-27.
• [21]Traish AM, Guay A, Feeley R, Saad F: The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Andol 2009, 30(1):10-22.
• [22]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
• [23]Muller M, Grobbee DE, den Tonkelaar I, Lamberts SW, van der Schouw YT: Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005, 90(5):2618-2623.
• [24]Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB: Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006, 91(3):843-850.
• [25]Traish AM, Saad F, Guay A: The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Andol 2009, 30(1):23-32.
• [26]Dandona P, Dhindsa S, Chandel A, Chaudhuri A: Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med 2009, 121(3):45-51.
• [27]Saad F, Gooren LJ: The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. J Obes 2011, 2011:471584.
• [28]Svartberg J, von Muhlen D, Sundsfjord J, Jorde R: Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 2004, 19(7):657-663.
• [29]Rosmond R, Wallerius S, Wanger P, Martin L, Holm G, Bjorntorp P: A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. J Intern Med 2003, 254(4):386-390.
• [30]Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB: Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000, 23(4):490-494.
• [31]Selvin E, Feinleib M, Zhang L, Rohrmann S, Rifai N, Nelson WG, Dobs A, Basaria S, Golden SH, Platz EA: Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007, 30(2):234-238.
• [32]Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ: Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 2007, 92(11):4254-4259.
• [33]Basaria S: Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth. J Andol 2008, 29(5):534-539.
• [34]Jones TH: Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. J Diabetes 2010, 2(3):146-156.
• [35]Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R: Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008, 20(4):378-387.
• [36]Boyanov MA, Boneva Z, Christov VG: Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003, 6(1):1-7.
• [37]Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, Lindstedt G, Bjorntorp P: The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992, 16(12):991-997.
• [38]Haider A, Gooren LJ, Padungtod P, Saad F: Beneficial effects of 2 years of administration of parenteral testosterone undecanoate on the metabolic syndrome and on non-alcoholic liver steatosis and C-reactive protein. Horm Molec Biol Clin Invest 2010, 1(1):27-33.
• [39]Pitteloud N, Hardin M, Dwyer AA, Valassi E, Yialamas M, Elahi D, Hayes FJ: Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. J Clin Endocrinol Metab 2005, 90(5):2636-2641.
• [40]Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, Tripathy D, Yialamas M, Groop L, Elahi D, Hayes FJ: Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005, 28(7):1636-1642.
• [41]Rabiee A, Dwyer AA, Caronia LM, Hayes FJ, Yialamas MA, Andersen DK, Thomas B, Torriani M, Elahi D: Impact of acute biochemical castration on insulin sensitivity in healthy adult men. Endocr Res 2010, 35(2):71-84.